Ubrogepant sustains its favourable effect for migraine regardless of demographic and clinical features, and concomitant medication use, according to pooled results of the ACHIEVE I and II studies presented at AHS 2020.
There appears to be no benefit to taking dietary antioxidants, such as vitamins and carotenoids, in terms of reducing the risk of developing Parkinson’s disease (PD) in Asians, as shown in a Singapore study.
Consistent with the overall outcome of the phase III EF-14 study, elderly patients with newly diagnosed glioblastoma multiforme (GBM) treated with tumour-treating fields (TTFields) and temozolomide (TMZ) showed significantly better overall survival (OS) vs patients on TMZ alone, according to a post-hoc analysis presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.
Long-term use of onabotulinumtoxinA led to reductions in monthly headache days (MHDs) in adults with chronic migraine (CM), according to post hoc analyses of the COMPEL* study presented at the AHS 2020 virtual scientific meeting.
A retrospective cohort study of nearly 2,000 patients hospitalized with coronavirus disease 2019 (COVID-19) found a higher rate of ischaemic stroke compared with a cohort of patients with influenza A/B.
A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.